Baxter reports positive Phase III trial results of BAX 817
The trial was designed to evaluate the safety and efficacy of BAX 817 in male patients aged 12 to 65 years with hemophilia A or B with inhibitors
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.